Clinical Trials Using Fulvestrant

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fulvestrant. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-42 of 42

  • A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib / Letrozole Or Palbociclib / Fulvestrant In Women With Metastatic Breast Cancer

    This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib / fulvestrant and gedatolisib plus palbociclib / letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib / letrozole or palbociclib / fulvestrant.
    Location: 2 locations

  • A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

    This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS. The first subject of each of five groups will receive fulvestrant intramuscularly. The subsequent 5 subjects of each group will receive fulvestrant by intraductal instillation. All subjects will be monitored for systemic and local adverse events during the procedure, and following the procedure until mastectomy or lumpectomy. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.
    Location: 2 locations

  • Aromatase Inhibitor Therapy with or without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer with an ERS1 Activating Mutation, the INTERACT Study

    This phase II trial studies how well letrozole, anastrozole, or fulvestrant work when given together with ribociclib, palbociclib, and / or abemaciclib in treating patients with hormone receptor (HR) positive breast cancer that has spread to other places in the body (metastatic) and has an ERS1 activating mutation. Letrozole, anastrozole, ribociclib, palbociclib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. It is not yet known if giving letrozole, anastrozole, or fulvestrant with ribociclib, palbociclib, and / or abemaciclib will work better in treating patients with breast cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ipatasertib with Aromatase Inhibitor, Fulvestrant, and / or Palbociclib in Treating Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

    This phase Ib trial studies the side effects and best dose of ipatasertib when given together with aromatase inhibitor (letrozole, anastrozole, or exemestane), fulvestrant, and / or palbociclib in treating patients with hormone receptor positive, HER2 negative breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Stopping (inhibiting) an enzyme called Akt in tumor cells may stop cancer resistance to standard of care treatment. Ipatasertib is a type of inhibitor that may stop the growth of tumor cells by inhibiting Akt. Through the different combinations of ipatasertib and the standard of care drugs, the chance of cancer cells becoming resistant to the standard of care drugs may decrease, causing cancer cells to stop growing and spreading.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Palbociclib, Bosutinib, and Fulvestrant for the Treatment of Metastatic Hormone Receptor Positive and HER2 Negative Breast Cancer Refractory to Aromatase Inhibitors

    This trial studies the side effects and best dose of bosutinib and palbociclib when given together with fulvestrant in treating patients with hormone receptor positive and HER2 negative breast cancer that has spread to other places in the body (metastatic) and does not respond to aromatase inhibitor therapy (refractory to aromatase inhibitors). Bosutinib and palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. This study is being done because it is not known if this combination therapy can be safely used at effective doses, preventing or postponing the need to start treatment with chemotherapy.
    Location: MedStar Georgetown University Hospital, Washington, District of Columbia

  • Talimogene Laherparepvec with Paclitaxel or Endocrine Therapy in Treating Participants with Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer

    This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with paclitaxel or endocrine therapy in treating participants with breast cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body, cannot be removed by surgery, or has come back after. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made by the body or may may stop the growth of tumor cells by blocking estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with paclitaxel or endocrine therapy may work better in treating participants with HER2-negative breast cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Fulvestrant and Abemaciclib in Treating Patients with Stage III- IV Low Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This pilot phase II trial studies how well fulvestrant and abemaciclib work in treating patients with stage III-IV low grade serous ovarian, primary peritoneal, or fallopian tube cancer. Fulvestrant and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

    This is a modular, Phase I / II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.
    Location: 2 locations

  • FGFR Inhibitor Debio 1347 and Fulvestrant in Treating Patients with FGFR-Amplified Endocrine Receptor Positive Metastatic Breast Cancer

    This phase Ib / II trial studies the side effects and best dose of FGFR inhibitor Debio 1347 when given together with fulvestrant and to see how well they work in treating patients with FGFR-amplified endocrine receptor positive breast cancer that has spread to other places in the body (metastatic). FGFR inhibitor Debio 1347 may block some receptors that needed for cell growth. Estrogen can cause the growth of breast cancer cells. Drugs, such as fulvestrant, may lessen the amount of [hormone] made by the body. Giving FGFR inhibitor Debio 1347 and fulvestrant may work better in treating patients with FGFR-amplified endocrine receptor positive breast cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Fulvestrant, Palbociclib, and Erdafitinib in Treating Patients with Estrogen Receptor Positive, HER2 Negative, and FGFR Amplified Stage IV Breast Cancer That Is Recurrent or Cannot Be Removed by Surgery

    This phase Ib trial studies the side effects and best dose of erdafitinib when given together with fulvestrant and palbociclib in treating patients with estrogen receptor positive, HER2 negative, and FGFR amplified stage IV breast cancer that has come back or cannot be removed by surgery. Drugs used in chemotherapy, such as fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Palbociclib and erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving fulvestrant, palbociclib, and erdafitinib may work better in treating patients with breast cancer.
    Location: 6 locations

  • Fulvestrant or Tamoxifen Citrate in Treating Patients with Cyclin D1 and Estrogen Receptor Positive Breast Cancer

    This randomized phase II trial studies how well fulvestrant or tamoxifen citrate work in treating patients with cyclin D1 and estrogen receptor positive breast cancer. Drugs used in chemotherapy, such as fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Tamoxifen citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether fulvestrant or tamoxifen citrate works better in treating patients with breast cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Fulvestrant and Tamoxifen Citrate in Treating Patients with Estrogen Receptor Positive Metastatic Breast Cancer

    This randomized phase II trial studies how well fulvestrant and tamoxifen citrate work in treating patients with estrogen receptor positive breast cancer that has spread to other parts of the body. Estrogen can cause the growth of breast tumor cells. Hormone therapy using fulvestrant and tamoxifen citrate may fight estrogen receptor positive metastatic breast cancer by blocking the use of estrogen by the tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Study of ZW25 With Palbociclib Plus Fulvestrant in Patients With HER2+ / HR+ Advanced Breast Cancer

    This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and / or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Neo-adjuvant Abemaciclib with Fulvestrant for the Treatment of Hormone Receptor Positive Stage I-III Breast Cancer

    This phase II trial studies how well abemaciclib and fulvestrant work before surgery (neo-adjuvant) in treating patients with hormone receptor positive stage I-III breast cancer that has come back in the breast and has not spread to other distant organs (localized non-metastatic breast cancer) and demonstrates resistance to endocrine therapy. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast tumor cells. Fulvestrant may help fight breast cancer by blocking the use of estrogen by the tumor cells. Abemaciclib and fulvestrant may destroy as much cancer as possible that will allow a complete pathologic response to be achieved. A complete pathologic response is defined as the absence of breast cancer in the breast and / or the axillary (a person's armpit) lymph nodes in the surgical specimen.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Olaparib, Palbociclib, and Fulvestrant in Treating Patients with BRCA Mutation-Associated, Hormone Receptor-Positive, and HER2-Negative Advanced Breast Cancer

    This phase I / II trial studies the best dose and side effects of palbociclib when given together with olaparib and fulvestrant, and to see how well they work in treating patients with BRCA mutation-associated, hormone receptor-positive, HER2-negative breast cancer that has spread from its original site of growth to nearby tissues or lymph nodes and cannot be removed by surgery, or has spread to other places in the body (advanced). Palbociclib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anti-hormone therapy consisting of fulvestrant may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation. This trial studies the effectiveness of the combination of palbociclib, olaparib and fulvestrant.
    Location: 2 locations

  • A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

    The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.
    Location: 4 locations

  • Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

    This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may work better in treating patients with breast cancer.
    Location: 9 locations